Appropriateness of clinical criteria for the use of symptomatic slow-acting drug for osteoarthritis (SYSADOA). A Delphi method consensus initiative among experts in Italy
OsteoArthritis (OA) is a theme currently representing an emerging topic for its increasing incidence. It is well known that it is a chronic disease that could lead to important long-lasting disability; this generates increasing costs for the health care system. OA treatment options vary: localization, aetiology, grading and symptomatology should be considered before choosing the most adequate therapy. Currently, a modern approach to managing OA involves SYmptomatic Slow Acting Drugs in Osteo-Arthritis (SYSADOAs).